CAR T-cell therapies represent an promising area of innovation in the treatment of B-cell lymphomas, in which patient’s T cells are transduced with a viral vector to form a CAR, comprising a tumor-targeting antibody portion linked to TCR intracellular signal transduction domains, which bypasses MHC restrictions for tumor-cell recognition and killing (Ansell and Lin, 2020). The gene discussed is HLA-C; the disease is B-cell non-Hodgkin lymphoma.